Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA: 603707)

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	902.47	1,210	1,389	658.55	493.55	364.16
Short-Term Investments	-	-	-	-	-	10.46
Trading Asset Securities	1,052	429.66	1.3	259.8	845.79	56.64
Cash & Short-Term Investments	1,954	1,639	1,390	918.35	1,339	431.26
Cash Growth	-19.24%	17.96%	51.34%	-31.43%	210.56%	-0.81%
Accounts Receivable	953.34	771.68	974.11	897.75	788.11	407.75
Other Receivables	260.98	230.88	241.94	167.88	107.21	51.6
Receivables	1,214	1,003	1,216	1,066	895.31	459.34
Inventory	3,602	4,158	5,616	4,894	4,457	3,274
Prepaid Expenses	-	11.98	8.46	7.98	10.11	4.6
Other Current Assets	178.64	449.31	64.14	43.62	65.9	119.71
Total Current Assets	6,949	7,262	8,294	6,930	6,768	4,289
Property, Plant & Equipment	1,172	1,235	1,198	827.42	532.83	481.46
Long-Term Investments	81.92	72.48	61.6	26.39	3.26	0.94
Goodwill	126.25	127.61	125.48	114.87	117.56	125.69
Other Intangible Assets	171.31	174.1	118.96	123.85	105.37	77.41
Long-Term Deferred Tax Assets	251.27	348.4	101.47	34.54	21.65	13.27
Long-Term Deferred Charges	453.75	294.24	94.62	77.65	55.52	49.48
Other Long-Term Assets	221.18	10.38	16.31	82.34	116.08	41.4
Total Assets	9,427	9,524	10,010	8,217	7,720	5,078
Accounts Payable	539.26	537.74	505.12	458.87	502.22	487.67
Accrued Expenses	116.57	294.85	88.15	64.56	47.26	49.75
Short-Term Debt	1,474	1,567	1,957	1,571	2,132	1,368
Current Portion of Long-Term Debt	3.97	505.45	0.42	-	-	-
Current Income Taxes Payable	6.92	29.31	0.44	8.73	17.42	28.61
Current Unearned Revenue	26.75	35.93	38.22	25.07	29.08	36.77
Other Current Liabilities	55.04	116.18	115.44	138.56	77.65	62.14
Total Current Liabilities	2,223	3,086	2,705	2,266	2,806	2,033
Long-Term Debt	822.79	512.37	997.36	480.75	1,132	6.17
Long-Term Leases	10.79	13.23	15.94	-	-	-
Long-Term Unearned Revenue	69.74	76.57	84.99	65.51	38.15	34.85
Long-Term Deferred Tax Liabilities	33.43	37.33	39.99	1.42	-	-
Total Liabilities	3,160	3,726	3,843	2,814	3,976	2,074
Common Stock	1,616	1,617	1,617	1,244	934.16	718.47
Additional Paid-In Capital	590.74	601.02	603.59	987.96	157.77	356.37
Retained Earnings	3,982	3,540	3,915	3,123	2,485	1,895
Treasury Stock	-	-27.75	-32.82	-47.3	-14.43	-16.77
Comprehensive Income & Other	82.38	72.5	67.9	70.45	159.79	13.82
Total Common Equity	6,270	5,802	6,171	5,378	3,722	2,966
Minority Interest	-3.48	-3.47	-3.47	24.84	22.12	37.6
Shareholders' Equity	6,267	5,798	6,167	5,403	3,745	3,004
Total Liabilities & Equity	9,427	9,524	10,010	8,217	7,720	5,078
Total Debt	2,312	2,598	2,971	2,051	3,264	1,375
Net Cash (Debt)	-357.88	-958.38	-1,581	-1,133	-1,925	-943.27
Net Cash Per Share	-0.22	-0.61	-0.97	-0.72	-1.21	-0.60
Filing Date Shares Outstanding	1,616	1,473	1,653	1,543	1,662	1,554
Total Common Shares Outstanding	1,616	1,473	1,653	1,543	1,662	1,554
Working Capital	4,727	4,175	5,589	4,663	3,962	2,255
Book Value Per Share	3.88	3.94	3.73	3.49	2.24	1.91
Tangible Book Value	5,973	5,500	5,926	5,139	3,500	2,763
Tangible Book Value Per Share	3.70	3.73	3.58	3.33	2.11	1.78
Buildings	-	548.07	448.47	268.49	164.68	154.03
Machinery	-	1,212	981.72	751.74	606.4	389.11
Construction In Progress	-	79.74	250.62	215.26	99.68	64

Source: S&P Capital IQ. Standard template. Financial Sources.